An observational study of bariatric surgery on adiponectin expression, circulation and receptor number in obese patients.

The Univeristy of Auckland0 个研究点目标入组 45 人开始时间: 2011年5月23日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Phase 1 A Lean: BMI 18.5-25 kg/m2, weight stable and healthy.
•Accepted into the Auckland District Health Board Auckland City Hospital General Laparoscopic Upper GI Surgery Clinic. Accepts reversion to open surgery if necessary.
•Signed informed consent given.
•Phase 1 B Obese: BMI >40 or >35 kg/m2 with co-morbidities and weight stable.
•Accepted into the Auckland District Health Board Auckland City Hospital General Laparoscopic Upper GI Surgery Clinic. Accepts reversion to open surgery if necessary.
•Signed informed consent given.
•Phase 2: Body Mass Index (BMI) >40 kg/m2 or >35 kg/m2 plus co-morbidities of diabetes, polycystic ovary syndrome, fatty liver disease and severe dyslipidaemia.
•Accepted for Bariatric Surgery at Auckland City Hospital
•Signed informed consent given

•History of inflammatory or malignant disease.
•Previous obesity surgery – bariatric, liposuction, lipectomy or liposculpture
•Pregnant or breastfeeding
•Participation in another clinical trial
•No weight loss medication of weight programme attendance.
•No extreme food restriction and/or excessive physical activity and alters body composition in a short space of time.

发起方

The Univeristy of Auckland